Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

326 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-14

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate a new maintenance therapy with the aim of improving the outcome of patients with acute myeloid leukaemia (AML) and myelodysplasia (MDS) after stem cell transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

NCT01835587

Leukemia, Myeloid, Acute Myelodysplastic Syndromes

COMPLETED PHASE1/PHASE2

A Phase II Study of Maintenance With Azacitidine in MDS Patients

NCT00446303

Leukemia, Myelocytic, Acute Myelodysplastic Syndromes

TERMINATED PHASE2

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

NCT00350818

Myelodysplastic Syndrome Leukemia

COMPLETED PHASE1

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

NCT07094464

TP53-mutated MDS and AML Allogeneic Hematopoietic Stem Cell Transplantation

ACTIVE_NOT_RECRUITING PHASE1

Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS

NCT02204020

Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, two arm, double-blind, phase III clinical trial in adult patients with acute myeloid leukaemia (AML) and myelodysplasia (MDS) who have undergone an allogeneic stem cell transplant (allo-SCT) and are randomised to receive oral azacitidine or placebo upon engraftment for up to 12 months as maintenance therapy. Patients will be stratified by type of transplant (myeloablative/reduced intensity, age (\<60/≥ 60 years) and donor type (sibling/unrelated)).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia Myelodysplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Oral azacitidine (CC-486) matched placebo once daily for first 14 days of each 28 day cycle

Group Type PLACEBO_COMPARATOR

Matched placebo

Intervention Type DRUG

Oral azacitidine (CC-486) matched placebo tablet

Experimental Group

Oral azacitidine (CC-486) 200 mg once daily for first 14 days of each 28 day cycle

Group Type EXPERIMENTAL

Oral azacitidine

Intervention Type DRUG

Oral azacitidine (CC-486) 200 mg tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral azacitidine

Oral azacitidine (CC-486) 200 mg tablet

Intervention Type DRUG

Matched placebo

Oral azacitidine (CC-486) matched placebo tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CC-486 Oral azacitidine matched placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 16 at the time of signing the informed consent form
2. Patients with a diagnosis of any of the below:

* AML (CR1 or CR2) according to World Health Organization (WHO) classification;
* Secondary AML (defined as previous history of MDS, antecedent hematological disease or chemotherapy exposure; CR1 or CR2); or
* Advanced or high risk MDS with an IPSS-R of ≥3.5 (intermediate 3.5 or higher) including intermediate or high risk chronic myelomonocytic leukaemia (CMML) (e.g. CPSS int-2 or high risk) (as per IPSS-R)

undergoing allo-SCT using myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) preparative regimens, and with either peripheral blood or bone marrow as the source of hematopoietic stem cells.
3. At the time of allo-SCT

* No prior allo-SCT; and
* No more than 1 antigen mismatch at HLA-A, -B, -C, -DRB1 or -DQB1 locus for either related or unrelated donor; and
* No haplotype or cord blood donor; and
* Bone marrow blast \<5% for AML and \<10% for MDS patients
4. Able to commence therapy between 42 to 84 days following allo-SCT
5. Post-transplant bone marrow

1. AML patients - blast count ≤ 5% confirmed within 28 days prior to starting study therapy
2. MDS patients - confirmation of CR post-transplant with blast count ≤ 5% in bone marrow
6. Adequate neutrophil and platelet engraftment within 14 days prior to starting study therapy defined as:

* Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9/L on two consecutive testing without daily use of myeloid growth factor; and
* Platelet ≥ 50 x 10\^9/L on two consecutive testing without platelet transfusion within 1 week
7. Adequate organ function:

* Serum aspartate aminotransferase (AST) and alanine transaminase (ALT) \< 4 x upper limit of normal (ULN)
* Serum bilirubin \< 2 x ULN. Higher levels are acceptable if these can be attributed to active red blood cell (RBC) precursor destruction within the bone marrow (i.e., ineffective erythropoiesis) or Gilbert's syndrome
* Serum creatinine \< 2 x ULN
8. Adequate coagulation (Prothrombin time (PT) ≤ 15 seconds and partial thromboplastin time (PTT) ≤ 40 seconds)
9. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
10. Patients with adequately controlled GVHD (defined as GVHD grade \<II with concurrent use of corticosteroids equivalent of prednisone at a dose ≤ 0.5 mg/kg) can be included
11. Females of childbearing potential (FCBP) may participate, providing they meet the following conditions:

1. Agree to use at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomised partner) or practice true abstinence throughout the study, and for 6 months following the last dose of study therapy and
2. Have a negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at screening; and
3. Have a negative serum or urine (investigator's discretion) pregnancy test (sensitivity of at least 25 mIU/mL) within 72 hours prior to starting study therapy. This applies even if the subject practices complete abstinence from heterosexual contact.
12. Male patients with a female partner of childbearing potential must agree to the use of at least two physician-approved contraceptive methods throughout the course of the study and should avoid fathering a child during the course of the study and for 3 months following the last dose study therapy
13. Understand and voluntarily sign an informed consent from prior to any study related assessments or procedures being conducted
14. Able to adhere to the study visit schedule (i.e., clinic visits at the study sites are mandatory, unless noted otherwise for study visits) and other protocol requirements

Exclusion Criteria

1. Use of any of the following after transplantation and prior to starting study therapy:

* Any chemotherapy used for adjuvant therapy
* Unlicensed investigational agents/therapies used within 28 days prior to starting study therapy
* Azacitidine, decitabine or other hypomethylating agent (HMA)
* Lenalidomide, thalidomide and pomalidomide used within 28 days prior to starting study therapy
2. Subjects who have undergone a haploidentical or cord blood transplant
3. Active GVHD grade II or higher (acute GVHD Clinical Staging and Grading)
4. Concurrent use of corticosteroids equivalent of prednisone at a dose \> 0.5 mg/kg
5. Known active viral infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV)
6. Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
7. History of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), celiac disease (i.e., sprue), prior gastrectomy or upper bowel removal, or any other GI disorder or defect that may interfere with the absorption, distribution, metabolism or excretion of the investigational medicinal products (IMPs) and/or predispose the subject to an increased risk of gastrointestinal toxicity prior to allo-SCT
8. Idiopathic thrombocytopenic purpura (ITP), disseminated intravascular coagulation, haemolytic uremic syndrome, thrombotic thrombocytopenic purpura (TTP)
9. History of prior malignancies, except: lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ, Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis (TNM) clinical staging system), previous MDS, CMML, myeloproliferative neoplasms (MPN) resulting in secondary AML. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent \< 5 years previously will not be allowed.
10. Significant active cardiac disease within the previous 6 months, including:

* New York Heart Association (NYHA) class III or IV congestive heart failure
* Unstable angina or angina requiring surgical or medical intervention; and/or
* Myocardial infarction
11. Known or suspected hypersensitivity to azacitidine or mannitol
12. Pregnant or lactating females
13. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating in the study.
14. Any condition including the presence of laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study
15. Any condition that confounds the ability to interpret data from the study

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No